XML 79 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
Stockholders' Equity - Narrative (Details) - USD ($)
 12 Months Ended
Nov. 09, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
May 16, 2023
Mar. 31, 2023
Jun. 24, 2022
Class of Stock [Line Items]              
Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)       $ 326.40      
Common stock, shares issued (in shares) [1]   22,793,075 21,090,938        
Allocated share-based compensation expense   $ 10,400,000 $ 22,200,000 $ 25,000,000      
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized   $ 4,300,000 $ 10,500,000        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition   1 year 3 months 18 days 1 year 7 months 6 days        
Number of options outstanding to purchase common stock (in shares)   1,128,864 1,018,095        
Aggregate intrinsic value of options outstanding   $ 2,000          
Aggregate intrinsic value for options exercisable   $ 1,000          
Options exercisable, remaining contractual term   5 years 6 months          
Number of options expected to vest (in shares)   1,128,864          
Options, expirations in period, weighted average exercise price (in dollars per share)   $ 38.86 $ 101.64 $ 54.72      
Options, expirations in period (in shares)   9,357 6,437 583      
Options, grants in period, weighted average grant date fair value (in dollars per share)   $ 11.19 $ 28.08 $ 91.32      
Proceeds from stock options exercised   $ 0 $ 283,000 $ 6,700,000      
Options, exercises in period, aggregate intrinsic value     81,000 7,000,000      
McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim              
Class of Stock [Line Items]              
Shares issued in settlement (in shares)           760,083  
Nonemployee              
Class of Stock [Line Items]              
Allocated share-based compensation expense   $ 669,000 1,300,000 1,400,000      
Number of options outstanding to purchase common stock (in shares)   61,808          
Research and Development Expense              
Class of Stock [Line Items]              
Allocated share-based compensation expense   $ 4,500,000 8,800,000 13,400,000      
General and Administrative Expense              
Class of Stock [Line Items]              
Allocated share-based compensation expense   $ 5,900,000 $ 13,400,000 $ 11,600,000      
Restricted Stock Units (RSUs)              
Class of Stock [Line Items]              
Number of shares of unvested restricted stock units and options outstanding (in shares)   274,794 212,964        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized   $ 3,500,000 $ 7,200,000        
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition   1 year 6 months 1 year 8 months 12 days        
Aggregate intrinsic value of unvested   $ 1,700,000          
Aggregate intrinsic value of vested   $ 1,300,000          
RSU's expected to vest (in shares)   274,794          
Weighted average grant date fair value (in dollars per share)   $ 10.34 $ 37.44 $ 124.44      
Restricted Stock Units (RSUs) | Former President and Chief Executive Officer              
Class of Stock [Line Items]              
Awards settled in cash, percentage   50.00%          
2016 Incentive Plan              
Class of Stock [Line Items]              
Number of shares of vested restricted stock outstanding under the plan (in shares)   262,641          
Number of common stock shares outstanding under the Incentive Plan (in shares)   961,499          
Vesting period of incentive plan   3 years          
Contractual year term of incentive plan   10 years          
2022 Inducement Plan              
Class of Stock [Line Items]              
Reserved number of shares under the Incentive Plan (in shares)             166,666
Number of shares available for grants under the Incentive Plan (in shares)   125,575          
Number of common stock shares outstanding under the Incentive Plan (in shares)   27,759          
Number of shares of unvested restricted stock units and options outstanding (in shares)   10,278          
2007 Incentive Plan              
Class of Stock [Line Items]              
Number of common stock shares outstanding under the Incentive Plan (in shares)   136,456          
Vesting period of incentive plan   3 years          
Contractual year term of incentive plan   10 years          
2023 Incentive Plan              
Class of Stock [Line Items]              
Reserved number of shares under the Incentive Plan (in shares)         1,166,666    
Number of shares available for grants under the Incentive Plan (in shares)   1,334,012          
Number of common stock shares outstanding under the Incentive Plan (in shares)   3,150          
Number of shares of unvested restricted stock units and options outstanding (in shares)   1,875          
Vesting period of incentive plan   3 years          
Contractual year term of incentive plan   10 years          
Series C Preferred Stock              
Class of Stock [Line Items]              
Convertible preferred stock, shares issued upon conversion (in shares)       275      
Common stock | 2021 Sales Agreement              
Class of Stock [Line Items]              
Common stock aggregate offering price $ 300,000,000            
Sales Agents will be entitled to compensation 3.00%            
Stock sale agreement, aggregate number of shares issued (in shares)   875,305 2,870,478        
Sales made at a weighted average price (in dollars per share)   $ 6.33 $ 29.34        
Stock sale agreement, aggregate proceeds from issuance of stock   $ 5,500,000 $ 83,000,000        
Remaining authorized amount   $ 161,800,000          
[1]
(1) The Company effected a reverse stock split of its outstanding shares of common stock on January 24, 2024 where every twelve shares of its common stock issued and outstanding was converted into one share of common stock. Any fractional post-split shares as a result of the reverse split were paid in cash. Shareholders of the Company authorized the Board of Directors to approve the reverse stock split at a special meeting of stockholders held on January 12, 2024. Outstanding share amounts have been restated to reflect the reverse stock split on a retroactive basis for all periods presented.